Published by Global Banking & Finance Review®
Posted on August 11, 2025
2 min readLast updated: January 22, 2026
Add as preferred source on GoogleDanone introduces Oikos Fusion drink for weight loss drug users, focusing on muscle retention with protein and vitamin D. Available at Walmart.
By Jessica DiNapoli
NEW YORK (Reuters) -Danone is introducing an Oikos brand drink targeting U.S. consumers using weight loss medications such as Wegovy, pledging the dairy-based beverage helps address the common concern of retaining muscle.
Patients on GLP-1 medications like Zepbound often shed valuable muscle rather than fat, worrying doctors and requiring diet changes, such as eating more protein.
Danone's new drink, called Oikos Fusion, has nutrients such as vitamin D and whey protein that the French company says help build and maintain muscle.
Danone is the latest food maker seizing the opportunity to sell new products to consumers dropping weight with GLP-1s, which users usually inject and are sometimes called "the shot."
The market is set to grow as drug makers look to develop the appetite-suppressing medication in pill form.
U.S. packaged food maker Conagra started labeling its Healthy Choice frozen meals "GLP-1" friendly, while rival Nestle launched Vital Pursuit to serve those on the medicine.
The frozen pizzas and pasta bowls generally offer higher amounts of protein and come in smaller portions.
Danone earlier this year introduced another high-protein Oikos smoothie to compete with Coca-Cola's wildly popular Fairlife. PepsiCo is also getting into "liquid protein" as Americans add more to their diet.
Danone's sales in North America grew more than 2% in its second quarter, in part because of Oikos, which is mostly a yogurt brand.
"This is a brand that has been growing at a rapid pace in the marketplace and strategically expanding," said Rafael Acevedo, president of yogurt at Danone North America.
Single bottles of the new drink will first be sold in Walmart for $2.12.
(Reporting by Jessica DiNapoli in New York; Editing by Kirsten Donovan)
Danone has introduced a new drink called Oikos Fusion, targeting U.S. consumers using weight loss medications.
Oikos Fusion contains nutrients such as vitamin D and whey protein, which Danone claims help build and maintain muscle.
The market is set to grow as drug makers look to develop appetite-suppressing medications in pill form, with food makers also introducing products for consumers using GLP-1s.
Single bottles of the new drink will first be sold in Walmart for $2.12.
Other companies like Conagra and Nestle are also targeting this market, with Conagra labeling its meals as 'GLP-1 friendly' and Nestle launching Vital Pursuit.
Explore more articles in the Headlines category
